Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsSharp-Health-Plan FEHB Formulary Coverage & PA | O…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentSharp-Health-PlanPolicy N/A

    FEHB Prescription Drug List (Formulary) — Outpatient Prescription Drug Coverage

    Customize your policy alerts

    Sign up for all Sharp-Health-Plan policy alerts

    Know when Sharp-Health-Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the Sharp Health Plan formulary (list of covered outpatient prescription drugs) applicable to FEHB plans and governs covered drugs, tiers, and related formulary policies for plan members and providers.

    Policy Summary
    PayerSharp-Health-Plan
    PolicyFEHB Prescription Drug List (Formulary) — Outpatient Prescription Drug Coverage
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewApr 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug is designated PA or when requesting exceptions to quantity limits or step therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    FEHBplans covered
    Apr 2026last updated
    15+therapeutic sections
    electronicversion
    72/24hPA decision timeframes

    Coverage Rules and Utilization Management

    General coverage conditions and utilization management

    Covered when meeting formulary placement and any listed coverage requirements or limits.

    Formulary inclusion and benefit type: Drug must be FDA-approved and listed on the outpatient prescription drug Formulary to be covered under the pharmacy benefit; physician‑administered or self‑injectable Medical Benefit drugs are covered under the Medical Benefit.

    See Introduction for pharmacy vs Medical Benefit distinction (chunk 22).

    Prior Authorization requirement: If a drug is marked PA or PA**, the Prescribing Provider must request Prior Authorization; PA** applies when Step Therapy has not been met and a PA may be requested to bypass steps.

    PA requests decided within 72 hours for non‑urgent, 24 hours for urgent/exigent (chunk 35).

    Step Therapy requirement: If a drug is marked ST, coverage depends on prior use of specified alternative(s); providers may request a step therapy exception via the Prior Authorization process when medically necessary.
    Policy Summary
    PayerSharp-Health-Plan
    PolicyFEHB Prescription Drug List (Formulary) — Outpatient Prescription Drug Coverage
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewApr 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug is designated PA or when requesting exceptions to quantity limits or step therapy.
    SourceLink
    On This Page
    Coverage Rules and Utilization ManagementCode Tables, Quantity Limits, and Key ValuesPrior Authorization, Documentation, and Denial RisksInitial Therapy and Fill LimitsStep Therapy Rules and TablesQuantity Limit Examples and EnforcementWhere Drugs Are Covered (Pharmacy vs Medical/Specialty)Formulary Background and ScopeKey Terms and Symbols

    See 'What is Step Therapy?' and PA** description (chunks 36, 38).

    Quantity Limits: Drugs marked QL are limited to a specified quantity per prescription/time period; requests for quantities beyond the QL require a Prior Authorization with documentation of medical necessity.

    Quantity Limits exist to address safety/overdose/abuse/usual dosing and are enforced per chunk 37.

    Step therapy for triptans

    Covered when ALL of the following are met for the listed step therapy groups.

    Triptan (ONZETRA XSAIL) step: Member has filled a prescription of a generic triptan (almotriptan, eletriptan, frovatriptan, sumatriptan, naratriptan, rizatriptan, rizatriptan ODT, zolmitriptan, or sumatriptan‑naproxen) for at least a 30‑day supply within the past 180 days.>=30 day supply within 180 days

    Meets step therapy requirement for ONZETRA XSAIL when documented; see Step Therapy Group HPGST TRIPTANS 410‑D (chunk 72).

    Step therapy for opioid products

    Covered when ANY of the following opioid exposure conditions are met.

    Opioid exposure criteria: Member has filled a cumulative 7‑day or greater supply of an immediate‑release opioid within the past 90 days OR has been receiving an extended‑release opioid for a cumulative 30 days or greater within the past 90 days.7‑day IR or 30‑day ER within 90 days

    Satisfies step therapy for the listed ER opioid group (chunk 72).

    Amphetamines (authorization and quantity limits)

    Covered with prior authorization and quantity limits for listed amphetamine products.

    Amphetamine PA and QL: Certain generic amphetamine products require Prior Authorization and are subject to specified Quantity Limits; PA is required for members age ≥ 19.age >= 19 for PA; per‑product QL (e.g., up to 360 tabs every 75 days)

    Exact QL and PA applicability depend on product strength/formulation (see amphetamine listings, chunk 73).

    Step therapy coverage criteria

    Step therapy groups with explicit prior‑fill requirements.

    Triptan Step Therapy: Member must have filled a generic triptan for at least a 30‑day supply within the past 180 days to meet the triptan group requirement for ONZETRA XSAIL.30‑day supply within 180 days

    HPGST TRIPTANS 410‑D (chunk 72)

    Opioid ER Step Therapy: Member must have either a cumulative ≥7‑day supply of an immediate‑release opioid within the past 90 days OR cumulative ≥30 days of an extended‑release opioid within the past 90 days to meet ER opioid group criteria.7‑day IR within 90 days OR 30‑day ER within 90 days

    Applies to OPIOID ER 2219‑M group (chunk 72)

    Opioid IR combination short supply: Coverage for immediate‑release opioid combination products is allowed up to a 7‑day supply when the member does not have at least a cumulative 7‑day opioid supply (IR or ER) within the past 90 days.<=7‑day supply when no prior 7‑day opioid supply in 90 days

    OPIOID IR COMBO PRODUCTS 1358‑E (chunk 72)

    PA and QL criteria

    Prior authorization and quantity limits for amphetamines and related agents.

    PA requirement: Many amphetamine products require Prior Authorization; PA is specifically required for listed strengths/formulations when member age is greater than or equal to 19.age >= 19 for PA

    See individual product rows for PA flags (chunks 73, 75, 79)

    Quantity limits are specified per product and commonly expressed as 'X units every 75 days' (examples include 360 tabs every 75 days, 180 tabs every 75 days, 90 caps every 75 days, or 3600 mL every 75 days for oral solution).per‑product QL values

    Exact QL varies by strength/formulation (chunks 73, 75, 79)

    Coverage with prior authorization and quantity limits

    Covered when PA and quantity limits are met per product listing.

    General coverage conditions for listed stimulants: Product coverage requires adherence to any Prior Authorization (PA) indicated, compliance with specified Quantity Limits (QL), and adherence to any Medical Override (MO) rules noted for the product.see product‑specific QL values

    Many stimulant entries require PA for members age >= 19 (chunks 95–104)

    Coverage conditions and utilization management

    Coverage of listed opioid products is conditional and subject to the following utilization management constraints.

    Utilization controls apply: Many opioid products are subject to Prior Authorization (PA), Step Therapy (ST), and Quantity Limits (QL); high‑strength formulations frequently require PA.

    See individual product rows for specific PA/ST/QL flags (chunks 126–136)

    Initial‑fill age‑based limits: Many oral and liquid opioid products are subject to an initial 7‑day supply limit; if patient age is 19 or younger, an initial 3‑day limit applies where specified.7‑day (adult) / 3‑day (<20)

    Applies where explicitly stated in opioid listings (chunks 129, 135, 136)

    Formulation‑specific QLs: Products have numeric quantity limits over 25‑day or 15‑day windows (examples: hydromorphone liquid 600 mL per 25 days; tramadol solution 1800 mL per 25 days; various tablets/caps with per‑25‑day caps).varies by product

    Exact QL values listed per product (chunks 129, 135, 142, 143)

    Age exclusions: Some formulations are not available under age 12 and other products have explicit pediatric initial‑fill restrictions.age <12 excluded for some products; shorter initial limit for age <=19

    See tramadol and acetaminophen/codeine entries (chunks 142–146)

    Product-specific coverage controls

    Coverage and utilization controls apply per listed product as follows (examples from this segment):

    XTAMPZA ER formulations: Covered with Step Therapy (ST) where indicated and Quantity Limit of 60 capsules every 25 days; Prior Authorization (PA) or PA** applies for many strengths; high strengths require PA.60 caps every 25 days

    XTAMPZA ER entries and flags (chunks 144–145)

    Acetaminophen with codeine formulations: Covered subject to Step Therapy (ST), Quantity Limits (e.g., 2700 mL or 400/360/180 tabs every 25 days depending on strength), PA** status, and initial supply limits; many formulations are not available under age 12.2700 mL/25 days or tab limits per strength

    See acetaminophen/codeine rows (chunks 144–146)

    Hydrocodone/acetaminophen formulations: Many strengths require PA or PA** and have QL (e.g., 240 tabs every 25 days); initial supply limits apply and some ER formulations are subject to ST.240 tabs every 25 days (example)

    Hydrocodone listings and ST/PA flags (chunks 148, 151, 152)

    Buprenorphine (BELBUCA and other formulations): BELBUCA films have ST and QL (60 films every 25 days) with PA** noted; higher strengths are PA or require PA; other buprenorphine patches/films have assorted ST/QL/PA statuses.60 films every 25 days

    BELBUCA and buprenorphine entries (chunks 155, 157)

    Butalbital‑containing combinations: Butalbital combination products have numeric QLs (e.g., 48 caps every 25 days) and may be unavailable for certain pediatric ages per formulary notes.48 caps every 25 days

    Butalbital listings (chunk 146 and related rows)

    General formulary coverage conditions

    Covered when plan‑specified tier and coverage requirements are met.

    Formulary coverage conditions: Coverage requires the drug to be on the Formulary at the assigned drug tier and adherence to any coverage requirement code (e.g., MO) and Quantity Limit (QL) specified for the product.

    MO and QL flags imply plan‑level management or medical override processes (chunks 180, 183, 187).

    Formulary tiering and shorthand coverage indicators

    Coverage stance by product is indicated via drug tier and short coverage requirement codes.

    Coverage indicators: Each product lists a DRUG TIER and a COVERAGE REQUIREMENTS AND LIMITS code (examples: MO, PA, QL, ST). Where PA or MO appear, prior authorization or medical override processes are implied and must be followed.

    Examples of Tier = 1 generics and Tier = 2 branded agents with MO/PA flags are shown in the antidiabetic and injectable segments (chunks 252, 263, 266).

    The Table of Contents includes an EXCLUSIONS AND LIMITATIONS TO THE OUTPATIENT PRESCRIPTION DRUG BENEFIT section, indicating that the formulary defines specific exclusions and limitations to the outpatient pharmacy benefit.

    Drugs and supplies that meet any of the outpatient prescription drug benefit exclusion criteria described in the FEHB Brochure are not eligible for an Exception Request under the pharmacy benefit. The Formulary distinguishes pharmacy-covered drugs from Medical Benefit drugs (physician-administered or self‑injectable) and refers providers and members to the FEHB Brochure for specific cost‑sharing, exclusions, and limitations.

    The formulary lists multiple explicit exclusions to the outpatient prescription drug benefit, including drugs dispensed by non‑Plan pharmacies except for emergency care; drugs prescribed by non‑Plan providers without authorization; most over‑the‑counter products (with limited exceptions); vitamins (other than listed pediatric/prenatal); cosmetic or hair‑loss indications; herbal/nutritional supplements; dental‑only products; travel/work immunizations; drugs obtained outside the U.S. (except urgent/emergency); weight‑loss drugs except when meeting strict program criteria for severe Class III obesity; off‑label uses not supported by standard compendia or adequate peer‑reviewed evidence; replacement of lost/stolen medications; compounded medications without PA; and services/supplies related to non‑covered benefits.

    Abortions are excluded from coverage under the outpatient prescription drug benefit except when coverage is required to save the life of the mother or when the pregnancy resulted from rape or incest.

    This section does not state additional clinical exclusions but does note an age‑based prior authorization requirement for certain amphetamine products: prior authorization is required for listed amphetamine formulations when the member is age ≥ 19.

    No other explicit exclusions are listed in the provided excerpt for the coverage criteria section.

    In the examined chunks there are no additional explicit clinical exclusions identified beyond those already described elsewhere in the exclusions section.

    Several tramadol extended‑release formulations are listed as Not available under age 12 in the formulary entries.

    Multiple opioid combination products (for example, acetaminophen/codeine and various butalbital combinations) are listed with an explicit age exclusion: they are Not available under age 12 according to the product rows.

    No explicit exclusions are specified in this excerpt of the formulary drug‑tier and coverage‑requirements section.

    RELION (the store‑brand insulin) is explicitly noted as not covered for multiple NOVOLIN and NOVOLOG product entries (the rows state ‘RELION not covered’ next to those insulin lines).

    Off‑label uses are not covered under the outpatient prescription drug benefit unless the use is recognized in an accepted standard reference compendium (e.g., USP‑DI, AMDE, AHFS) or the safety and effectiveness for that indication have been demonstrated by at least two studies published in a major peer‑reviewed journal.

    No statements explicitly labeled 'not medically necessary' appear in the provided chunks of this section.

    In this excerpt there are no explicit 'not medically necessary' determinations documented within the listed product rows.

    Code Tables, Quantity Limits, and Key Values

    Prior Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior Authorization (PA), Step Therapy (ST), Quantity Limits (QL), Specialty (SP), and Mail Order (MO) designations on the formulary require action by the prescribing provider. Drugs marked PA or PA** require a prior authorization request; PA** indicates PA is required if Step Therapy has not been met. Drugs marked ST require that specified prior drugs or fills be tried (step therapy) before coverage; documentation of prior fills or a Step Therapy Exception request may be submitted when medically necessary. QL and MO-coded items may require PA or a medical override for quantities or dispensing channel changes. Specialty drugs (SP) must be filled through the Sharp Health Plan Specialty Pharmacy network.

    • PA, PA**: Prescriber must request prior authorization via phone, fax, or electronic prior authorization form. Non-urgent requests: decision within 72 hours; urgent/exigent requests: decision within 24 hours.
    • ST: Step Therapy requires prior use (filled prescriptions) of specified alternative drugs. If step criteria are not met, the provider may request a Step Therapy Exception using the PA process. Incomplete requests will trigger a notice requesting additional information and may delay or deny approval.
    • QL: Quantity limits are enforced; providers can request quantities above the QL via PA with medical necessity documentation.
    • SP: Specialty drugs require fill at Sharp Health Plan Specialty Pharmacy and are typically limited to 30-day supplies.
    Step Therapy

    Step Therapy Requirements and Triptan/Opioid Rules

    Step Therapy criteria are defined in the Step Therapy Criteria section. Examples include triptans and opioid step therapy groups: for ONZETRA XSAIL (triptan), coverage requires a filled prescription for a generic triptan for at least a 30-day supply within the prior 180 days. Opioid ER/IR groups require prior fills—coverage for opioid ER agents is contingent on prior cumulative use of immediate-release opioids or prior ER use as specified. Failure to meet step therapy will likely result in denial unless an exception is approved.

    • Triptans (HPGST TRIPTANS 410-D): fill of a generic triptan (e.g., sumatriptan, rizatriptan, zolmitriptan) for ≥30 days in the past 180 days required.
    • Opioid ER group (OPIOID ER 2219-M): coverage if member has ≥7 cumulative days of immediate‑release opioid fills in past 90 days OR ≥30 cumulative days of extended‑release opioid fills in past 90 days.
    • Opioid IR combo products: up to a 7‑day supply allowed if no opioid fills (IR or ER) in past 90 days.
    Prior Authorization

    Products Frequently Requiring Prior Authorization

    Many therapeutic classes and specific high‑risk or high‑cost products require prior authorization, including stimulants, wakefulness agents, amphetamines, methylphenidate patches, certain immunomodulators and PDE4 inhibitors (e.g., upadacitinib, tofacitinib, apremilast), selected injectables and GLP‑1/GIP agents (e.g., tirzepatide, semaglutide, dulaglutide), and numerous opioid formulations (especially high‑strength ER products and fentanyl patches). MO-coded drugs frequently require plan management or prior authorization/medical override.

    • Amphetamines and many stimulants: PA required for members ≥19; QL and MO often applied (examples: multiple amphetamine and methylphenidate formulations).
    • Methylphenidate transdermal patches: PA required for members age ≥19 and subject to QL.
    • Immunomodulators/PDE4 inhibitors (RINVOQ, XELJANZ, OTEZLA): SP and PA with quantity limits and specialty routing.
    • Opioids: many ER and high‑strength opioid products require PA or PA**; step therapy applies to certain ER opioids and some fentanyl patches.
    • GLP‑1/GIP and tirzepatide agents (MOUNJARO, OZEMPIC, RYBELSUS, TRULICITY, etc.): PA required; many are MO and/or specialty.
    Billing Rule

    MO/Quantity Limit and Medical Override Notes

    MO (Mail Order) and QL (Quantity Limit) designations indicate coverage constraints that may be enforced at the point of sale. MO-coded drugs are often subject to medical override or plan‑level management; claims exceeding QL or dispensed outside of allowed channels may be denied unless a PA or medical override is approved.

    • MO = maintenance drug eligible for up to a 90‑day mail order supply; some MO items still require PA or medical override.
    • Claims exceeding QL will be rejected or require PA with clinical justification.
    • Drugs annotated MO/QL: follow the plan PA/MO process to request overrides.
    Documentation Required

    Documentation and Submission Requirements

    Incomplete or missing documentation on PA or Step Therapy Exception requests will delay review and may result in denial. Providers should include relevant pharmacy fill history, clinical rationale, indication, patient age, and strength/quantity requested. Specialty drugs and requests for quantities above QL or for MO overrides typically require additional clinical documentation.

    • Required documentation: recent pharmacy fill history to support step therapy fills or prior opioid use, clinical indication, patient age when age‑based PA applies, and justification for quantities above QL.
    • Specialty drug requests: include diagnosis and prior therapies; prescriptions for SP drugs must indicate specialty dispensing.
    • Prescriptions must document strength and quantity to demonstrate compliance with QL and initial‑supply limits (e.g., initial 7‑day limit for many opioid products; 3‑day limits for certain ages).
    • If a request is incomplete, the plan will request additional information; unresolved incompleteness may lead to denial or delayed decision.
    Note

    Appeals and Reconsideration

    If Sharp Health Plan denies a PA, Formulary Exception, or Step Therapy Exception, the member, authorized representative, or prescribing provider may file an appeal or grievance. For pre‑service appeals, written reconsideration must be submitted within six months and include supporting documents (physician letters, medical records, EOBs). The plan will provide new evidence and rationale in a timely manner to allow response.

    • Appeals: submit within six months of the decision to the addresses and fax numbers in the formulary appeals section.
    • Include a statement explaining why the initial decision is wrong and copies of supporting medical documentation.
    • The plan has specific timelines for reconsideration decisions and will share any new evidence or rationale used in the decision.
    Denial Risk

    Denial Risks for Unmet Requirements

    Denial risks: prescribing or dispensing without required PA or without meeting Step Therapy criteria may result in claim denial. Requests for quantities exceeding QL, for non‑MO dispensing of MO‑coded drugs, or for coverage of Nonformulary drugs without an approved Formulary Exception are at high risk of denial.

    • PA listed on the formulary = obtain PA before dispensing to avoid denial.
    • Step Therapy noncompliance = likely denial unless exception approved.
    • High‑strength opioid or specialty product without PA = likely denied.
    Note

    Version and Availability

    Policy materials are subject to change; the electronic version on the Sharp Health Plan website is the authoritative source. Prior versions are no longer in effect. Members and providers should check the online formulary and Sharp Connect for the most up‑to‑date cost‑sharing and coverage details.

    • Electronic formulary: sharphealthplan.com/search-drug-list
    • Member cost sharing and plan details: sign in at sharphealthplan.com/login
    • This document is subject to change; prior versions are not in effect.

    Initial Therapy and Fill Limits

    Initial therapy for triptans

    Initial coverage rules for step therapy groups.

    Triptan initial requirement: To initiate coverage for ONZETRA XSAIL under the triptan step therapy group, the member must have a filled generic triptan 30‑day supply within the past 180 days.>=30 day supply within 180 days

    Matches Step Therapy Group HPGST TRIPTANS 410‑D (chunk 72)

    Initial therapy rules

    Initial coverage requirements implied by formulary entries.

    Initial authorization requirements: Initiation of many stimulant and related medications requires Prior Authorization; quantity limits and age‑based PA (age ≥ 19) apply where specified.see product‑specific QL values

    PA and QL flags are shown in stimulant listings (chunks 95, 99).

    Opioid initial supply

    Initial opioid supply limits.

    Opioid initial supply rules: Many opioid products are subject to an initial 7‑day supply limit; where the patient is age 19 or younger, an initial 3‑day limit applies as specified in product rows.7‑day (adult) / 3‑day (<20)

    Examples: codeine and other opioid listings note initial 7‑day limit and 3‑day limit for younger patients (chunk 125).

    Initial therapy limits

    Initial‑fill restrictions.

    Initial supply limits: Many oral and liquid opioid products are explicitly subject to an initial 7‑day limit for adults and an initial 3‑day limit for patients age 19 or younger; these restrictions apply to the first fill as noted in product entries.7‑day / 3‑day

    See hydromorphone, morphine, oxycodone and other opioid product rows (chunks 129, 135, 139).

    Initial supply restrictions

    Initial supply restrictions applied to many opioid products:

    Initial supply limits (summary): Subject to initial 7‑day limit for many products; subject to initial 3‑day limit for patients age 19 or younger when indicated in the listing.7 days (adult), 3 days (<20 yrs)

    Applies across multiple listed opioid formulations (chunks 146, 151).

    Tiering guidance

    Tier 1 generics and Tier 2 branded agents.

    Tier assignments: Many first‑line oral agents (metformin, sulfonylureas, TZDs, meglitinides) are assigned DRUG TIER = 1; many newer injectables and branded combination products are assigned DRUG TIER = 2.

    Tier assignments and MO/PA flags are shown in the antidiabetic/injectable segments (chunks 259, 270).